Liver cancer, of which hepatocellular carcinoma (HCC) is the dominant variety, represents the fourth leading cause of cancer deaths worldwide. For early HCC, surgical resection is the primary clinical practice. Still, most HCC patients are already in the middle and advanced stage at the time of diagnosis, so the best time for surgical resection is lost. For patients with advanced HCC, clinically available therapeutic methods are relatively limited, among which interventional therapy is the most commonly used first-line therapy. Interventional therapy has become an essential strategy of the clinical treatment for HCC because of its advantages in minimal invasion and accurate compliance. For example, Transarterial chemoembolization, Radiofrequency ablation, Microwave ablation. In recent years, new emerging interventional therapy has been developing towards non-invasive and intellectual development, playing an increasingly important role in the treatment of liver cancer.
The application of interventional therapy in the treatment for liver cancer is becoming more diversified. It can be involved in combination with cutting-edge therapies, such as immunotherapy, cell therapy and gene therapy. Interventional therapy-based comprehensive treatment of HCC has become one of the most promising areas in the field of tumor therapy, and in-depth research is imminent. The therapeutic strategies, efficacy and potential molecular mechanisms of interventional treatment for HCC are in urgent need of further exploration, and it is necessary to keep up with the frontier of disciplinary development.
For this Research Topic we are interested in Original Research, Review, Mini-Review, Opinion and Brief Research Reports that focus on (but are not limited to) the following topics:
• Transhepatic arterial chemoembolization
• Ablation (e.g. Radiofrequency ablation, Microwave ablation, and Cryoablation)
• Local radiotherapy
• Stent implantation
• Novel interventional technology
• Novel interventional materials
Liver cancer, of which hepatocellular carcinoma (HCC) is the dominant variety, represents the fourth leading cause of cancer deaths worldwide. For early HCC, surgical resection is the primary clinical practice. Still, most HCC patients are already in the middle and advanced stage at the time of diagnosis, so the best time for surgical resection is lost. For patients with advanced HCC, clinically available therapeutic methods are relatively limited, among which interventional therapy is the most commonly used first-line therapy. Interventional therapy has become an essential strategy of the clinical treatment for HCC because of its advantages in minimal invasion and accurate compliance. For example, Transarterial chemoembolization, Radiofrequency ablation, Microwave ablation. In recent years, new emerging interventional therapy has been developing towards non-invasive and intellectual development, playing an increasingly important role in the treatment of liver cancer.
The application of interventional therapy in the treatment for liver cancer is becoming more diversified. It can be involved in combination with cutting-edge therapies, such as immunotherapy, cell therapy and gene therapy. Interventional therapy-based comprehensive treatment of HCC has become one of the most promising areas in the field of tumor therapy, and in-depth research is imminent. The therapeutic strategies, efficacy and potential molecular mechanisms of interventional treatment for HCC are in urgent need of further exploration, and it is necessary to keep up with the frontier of disciplinary development.
For this Research Topic we are interested in Original Research, Review, Mini-Review, Opinion and Brief Research Reports that focus on (but are not limited to) the following topics:
• Transhepatic arterial chemoembolization
• Ablation (e.g. Radiofrequency ablation, Microwave ablation, and Cryoablation)
• Local radiotherapy
• Stent implantation
• Novel interventional technology
• Novel interventional materials
